Trials / Completed
CompletedNCT04119557
A Study of LY3471851 in Participants With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Nektar Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about the safety of LY3471851 when given by injection just under the skin to participants with psoriasis. The study will last up to 48 weeks and may include up to 23 visits to the study center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Administered SC |
| DRUG | LY3471851 | Administered SC |
Timeline
- Start date
- 2019-11-26
- Primary completion
- 2021-07-21
- Completion
- 2021-07-21
- First posted
- 2019-10-08
- Last updated
- 2024-02-20
Locations
24 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04119557. Inclusion in this directory is not an endorsement.